Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 58Multiple Myeloma 52Leukemia 48Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Myelodysplastic Syndromes 37Lymphoma, Non-Hodgkin 37Hodgkin Disease 36Lymphoma, Mantle-Cell 26Lymphoma, Large B-Cell, Diffuse 26Leukemia, Lymphocytic, Chronic, B-Cell 25Lymphoma, Follicular 22Breast Neoplasms 22Burkitt Lymphoma 21Lymphoma, B-Cell, Marginal Zone 16Congenital Abnormalities 15Lymphoma, Large-Cell, Immunoblastic 14Recurrence 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Sarcoma 12Neoplasms, Plasma Cell 12Hematologic Neoplasms 10Leukemia, Myelomonocytic, Juvenile 9Leukemia, Biphenotypic, Acute 9Blast Crisis 9Neoplasms 8Myeloproliferative Disorders 8Leukemia, Myelomonocytic, Chronic 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neuroblastoma 7

Interventions

Lenalidomide 2plerixafor 1ofatumumab 1SARS-CoV-2 inactivated vaccines 1Influenza Vaccines 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Agammaglobulinemia × Filgrastim × Clear all
NCT02231879 2023-04-07

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2/3 Completed
20 enrolled 10 charts

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡